Precision BioSciences to Present Late-Breaking HBV Data from ELIMINATE-B Trial
Event summary
- Precision BioSciences will present late-breaking biopsy and clinical data from the ELIMINATE-B trial at EASL Congress 2026 on May 27, 2026.
- The data pertains to PBGENE-HBV, a gene-editing therapy targeting chronic hepatitis B.
- The trial has received Fast Track designation from the FDA.
- An investor webcast will be held on May 27, 2026, at 8:00 AM EDT to discuss the findings.
The big picture
Precision BioSciences' presentation of late-breaking data from the ELIMINATE-B trial marks a critical juncture in the development of gene-editing therapies for chronic hepatitis B. The focus on eliminating cccDNA, a root cause of the infection, positions PBGENE-HBV as a potentially curative treatment. The strategic significance lies in the company's ability to leverage its ARCUS platform to target high-unmet medical needs, potentially reshaping the treatment paradigm for chronic hepatitis B.
What we're watching
- Clinical Efficacy
- How the late-breaking biopsy data will impact the perceived efficacy of PBGENE-HBV in eliminating cccDNA.
- Regulatory Pathway
- Whether the FDA's Fast Track designation will accelerate the approval process for PBGENE-HBV.
- Market Positioning
- The pace at which Precision BioSciences can differentiate itself in the competitive landscape of gene-editing therapies for chronic hepatitis B.
Related topics